The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
Open accessAbstract
BACKGROUND: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD. METHODS: Patients with COPD with a smoking history of ≥ 10 pack-years, post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30% predicted normal and FEV1/forced vital capacity < 0.70 were enrolled. Patients were randomized to double-blind treatment with NVA237 50 μg once daily or placebo for 26 weeks with inhaled/intranasal corticosteroids or H1 antagonists permitted in patients stabilized on them prior to study entry. The primary outcome measure was trough FEV1 at Week 12. RESULTS: A total of 822 patients were randomized to NVA237 (n = 552) or placebo (n = 270). Least squares mean (± standard error) trough FEV1 at Week 12 was significantly higher in patients receiving NVA237 (1.408 ± 0.0105 L), versus placebo (1.301 ± 0.0137 L; treatment difference 108 ± 14.8 mL, p < 0.001). Significant improvements in trough FEV1 were apparent at the end of Day 1 and sustained through Week 26. FEV1 was significantly improved in the NVA237 group versus placebo throughout the 24-hour periods on Day 1 and at Weeks 12 and 26, and at all other visits and timepoints. Transition dyspnoea index focal scores and St. George's Respiratory Questionnaire scores were significantly improved with NVA237 versus placebo at Week 26, with treatment differences of 1.04 (p < 0.001) and -2.81 (p = 0.004), respectively. NVA237 significantly reduced the risk of first moderate/severe COPD exacerbation by 31% (p = 0.023) and use of rescue medication by 0.46 puffs per day (p = 0.005), versus placebo. NVA237 was well tolerated and had an acceptable safety profile, with a low frequency of cardiac and typical antimuscarinic adverse effects. CONCLUSIONS: Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung function, improvements in dyspnoea, and health-related quality of life, and reduced the risk of exacerbations and the use of rescue medication. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01005901.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update
Fabbri, L. M., & Hurd, S. S. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00063703 · Cited by 1,277
Belman, M. J., Botnick, W. C., & Shin, J. W. (1996) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.153.3.8630581 · Cited by 402
Diaz, O., Villafranca, C., Ghezzo, H., Borzone, G., Leiva, A., Milic-Emil, J., & Lisboa, C. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.16b14.x · Cited by 300
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Seemungal, T. (2009) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3385 · Cited by 197
Cited by
Wedzicha, J. A., Decramer, M., Ficker, J. H., Niewoehner, D. E., Sandström, T., Taylor, A. F., D'Andrea, P., Arrasate, C., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70052-3 · Cited by 535
Self-citationPharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., & Banerji, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00200212 · Cited by 388
Self-citation
Metadata
- Authors
- D'Urzo, A., Ferguson, G. T., van Noord, J. A., Hirata, K., Martin, C., Horton, R., Lu, Y., Banerji, D., & Overend, T.
- Venue
- Respiratory Research
- Published
- 2011-12
- Volume
- 12
- Issue
- 1
- Pages
- 156-156
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W2134091333
- Cited by
- 176
- References
- 5
- FWCI
- 19.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. https://app.cochat.ai/papers/10.1186/1465-9921-12-156
- The paper
- D'Urzo, A., Ferguson, G. T., van Noord, J. A., Hirata, K., Martin, C., Horton, R., Lu, Y., Banerji, D., & Overend, T. (2011). Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Research. https://doi.org/10.1186/1465-9921-12-156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.